Mindfulness Interventions and Cutaneous T Cell Lymphoma (CTCL)
Stopped early · Not applicable
Conditions studied: Anxiety, Quality of Life
In brief
The primary objective is to assess the feasibly, adherence, and effects of mindfulness-based stress reduction (MBSR) on anxiety and health-related quality of life in adult patients with cutaneous T-cell lymphoma at the Yale Cancer Center/Smilow Cancer Hospital. Participants will attend group sessions led by an instructor experienced in MBSR in an academic setting. The mindfulness meditation group sessions will take place at the Smilow Cancer Center at the Yale New-Haven Hospital.
Key facts
- Study ID
- NCT03174808
- Run by
- Yale University
- People needed
- 3
- Starts
- 2017-08-20
- Expected to finish
- 2018-11-26
- Last updated by the study team
- 2019-11-27
Who can join
Age: 21 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Identified with lymphoma through the Yale Cancer Center Hematology Clinic.
- Access to mobile telephone/smartphone with text messaging plan in order to receive survey questions.
- Current CTCL patients in Dr. Foss's practice at the Yale Cancer Center.
You may not qualify if…
- Current regular mindfulness meditation activity (weekly or more frequent practice of self-defined meditation, formalized relaxation techniques, tai chi, and meditative yoga).
- Inability or unwillingness to give consent.
- Serious illness (including mental illness/psychopathology) within 90 days prior to screening, including hospitalization for chronic disease. Determination of 'serious' will be made by PI and research team. For example, unstable asthma, cancers (except non-melanoma skin cancer and CTCL), and schizophrenia will be considered 'serious,' while stable asthma, allergic rhinitis, esophageal reflux, generalized anxiety disorder, or attention deficit disorder will not be considered 'serious.
- Active participation (weekly or more often) in a cancer or chronic disease support group.
- Active substance abusers.
- Current suicidal ideation, operationally defined as affirmative responses on the Columbia-Suicide Severity Rating Scale (C-SSRS) at screening.
Where it is running
- Yale Cancer Center/Smilow — New Haven, Connecticut, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.